(Q37976137)

26 August 2017

title

Effect of statins therapy prior to percutaneous coronary intervention (English)

1 reference

26 August 2017

Jun Luo

1

1 reference

26 August 2017

Li Xu

series ordinal

2

1 reference

26 August 2017

Tianzheng Yu

series ordinal

3

1 reference

26 August 2017

Jiang Li

series ordinal

4

1 reference

26 August 2017

publication date

16 January 2012

1 reference

Journal of Interventional Cardiology

26 August 2017

published in

1 reference

26 August 2017

volume

25

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

156-162

1 reference

Relation of inflammation and benefit of statins after percutaneous coronary interventions

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Troponin I elevation and cardiac events after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

The effect of pre-hospital statins therapy on incidence of in-hospital death and total MACCE in patients with PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angiopl

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Ang

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Withdrawal of statins increases event rates in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Rapid Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition on Coronary Endothelial Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Use of statins and the subsequent development of deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

Effect of Two-Day Atorvastatin Pretreatment on Long-Term Outcome of Patients With Stable Angina Pectoris Undergoing Elective Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2011.00709.X

10.1111/J.1540-8183.2011.00709.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference